Nvidia Corp. will invest $1 billion over five years to establish a new artificial intelligence laboratory in collaboration with Eli Lilly & Co. The facility, located in Silicon Valley, aims to accelerate the application of AI in the pharmaceutical industry by leveraging Lilly's lab expertise.

AstraZeneca has entered an AI-driven research agreement with China's CSPC Pharmaceutical Group, potentially worth up to $5.3 billion, aimed at developing therapies for chronic diseases. This partnership follows previous collaborations and reflects AstraZeneca's strategy to enhance its presence in China's pharmaceutical market.